BCKDK (branched chain keto acid dehydrogenase kinase) is a serine/threonine kinase that serves as a critical metabolic regulatory hub controlling branched-chain amino acid (BCAA) catabolism and broader metabolic homeostasis. The primary function of BCKDK is to phosphorylate and inactivate the branched-chain α-ketoacid dehydrogenase (BCKDH) complex, the rate-limiting enzyme in BCAA catabolism, by phosphorylating the BCKDHA subunit at Ser-337 1. This phosphorylation disrupts substrate channeling between E1 and E2 components, effectively shutting down BCAA breakdown 1. Additionally, BCKDK phosphorylates cytosolic ACLY at Ser-455, coordinating BCAA metabolism with lipogenesis during feeding states 2. Disease relevance is extensive, as BCKDK overexpression contributes to obesity-associated insulin resistance through BCAA accumulation 3, promotes cancer metastasis in breast and lung cancers 45, and drives heart failure with preserved ejection fraction (HFpEF) through impaired cardiac lymphatic function 6. Clinically, BCKDK inhibition shows therapeutic promise, with selective inhibitors like BT2 and PF-07328948 demonstrating efficacy in treating diabetes, heart failure, and kidney dysfunction in preclinical models 3789, making BCKDK an attractive therapeutic target for cardiovascular-kidney-metabolic syndrome.